Huntington's disease (HD) is a lethal, neurodegenerative disorder caused by expansion of the polyglutamine repeat in the Huntingtin gene (HTT), leading to mutant protein misfolding, aggregation, and neuronal death. Feeding a Drosophila HD model cystamine, or expressing a transgene encoding the anti-htt intracellular antibody (intrabody) C4-scFv in the nervous system, demonstrated therapeutic potential, but suppression of pathology was incomplete. We hypothesized that a combinatorial approach entailing drug and intrabody administration could enhance rescue of HD pathology in flies and that timing of treatment would affect outcomes. Feeding cystamine to adult HD flies expressing the intrabody resulted in a significant, additional rescue of photoreceptor neurodegeneration, but no additional benefit in longevity. Feeding cystamine during both larval and adult stages produced the converse result: longevity was significantly improved, but increased photoreceptor survival was not. We conclude that cystamine-intrabody combination therapies can be effective, reducing neurodegeneration and prolonging survival, depending on administration protocols.
Introduction
HD is an autosomal, dominant, neurodegenerative disorder caused by mutations in the HTT gene that result from an expansion of a CAG repeat coding for a polyglutamine (polyQ) track in the N-terminal region of huntingtin (Htt) (Huntington's Disease Collaborative Research Group, 1993) . PolyQ expansions of ≥36 residues lead to protein aggregation, progressive age-dependent neuronal degeneration in the basal ganglia, and death (Ross and Poirier, 2004) . There is currently no effective treatment for HD.
Intrabodies are a relatively new prospective therapy for neurodegenerative diseases (Messer et al., 2009; Miller and Messer, 2005; Southwell et al., 2009; Stocks, 2006; Wang et al., 2008; Wolfgang et al., 2005 ). An intrabody is a single, stable, polypeptide containing one or both variable antibody regions that binds with high specificity to a target protein (Miller and Messer, 2005) . In cell culture, the C4 anti-htt single-chain Fv intrabody (C4-scFv) can maintain solubility of Htt protein by binding specifically to the protein's amino-terminal region and reducing formation of protein aggregates (Lecerf et al., 2001; Miller et al., 2005) . In a Drosophila HD model (Steffan et al., 2001 ), C4-scFv decreased mutant Htt aggregation, decreased neurodegeneration, and increased lifespan (Wolfgang et al., 2005) .
In the same Drosophila model, cystamine reduced neurodegeneration (Agrawal et al., 2005; Apostol et al., 2003; Marsh and Thompson, 2006) . Cystamine is also neuroprotective in mouse models of HD (Bailey and Johnson, 2005; Fox et al., 2004; Karpuj et al., 2002; Van Raamsdonk et al., 2005) . Cystamine is a competitive inhibitor of tissue transglutaminase (tTG). Therapeutically, cystamine may interfere with tTG-mediated glutamine crosslinking, reducing Htt aggregate formation (Agrawal et al., 2005; Apostol et al., 2003; Bailey and Johnson, 2005; Dedeoglu et al., 2002; Karpuj et al., 2002; Karpuj et al., 1999; Lorand and Conrad, 1984; Van Raamsdonk et al., 2005) .
In the fly neither C4-scFv nor cystamine alone were completely effective at abolishing the HD phenotype (Agrawal et al., 2005; Apostol et al., 2003; Wolfgang et al., 2005) . Previous studies suggest that additional therapeutic benefit can be achieved when various drugs are combined, perhaps through correcting multiple cellular pathologies associated with HD (Agrawal et al., 2005; Morton et al., 2005; Ryu et al., 2006; Sarkar et al., 2008; Schilling et al., 2001; Stack et al., 2006; Yang et al., 2009 ). These studies, however, did not explore the effect of timing of treatment administration. Treatment timing is highly relevant in humans because presymptomatic treatment is an option, due to HD's late onset (in most cases) and availability of accurate, predictive genetic diagnosis. Thus, we hypothesized that a combined treatment would result in additional protection, and that timing of treatment would affect outcomes. We report that a combination of cystamine and intrabody therapies produced an additional therapeutic Neurobiology of Disease 40 (2010) 130-134 
